HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $10 to $4.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $10 to $4.